文献速递胸部肿瘤

免疫治疗试验中动态治疗效应的贝叶斯解读

Bayesian interpretation of immunotherapy trials with dynamic treatment effects.
PubMed 文献 · Eur J Cancer · 2021-12-18

该研究选取14项未达到主要终点(总生存期)的免疫检查点抑制剂III期随机对照试验,采用贝叶斯Cox模型(含动态协变量系数与时间不变模型)重新分析。结果显示贝叶斯Cox模型在所有试验中均提示获益概率>79%,动态系数模型检测到风险比波动,2年总生存期增加是最可能的假设。作者建议在免疫治疗随机对照试验中逐步实施贝叶斯与动态分析。

要点

  • 在非比例风险条件下,最小可检测效应(δS)在所有病例中均优于观察到的真实获益。
  • Schoenfeld检验提示6/15例存在比例风险假设违背(p<0.05)。
  • 贝叶斯Cox模型显示所有试验获益概率>79%,治疗等效假设不太可能。

核心结论

  • 作者建议在所有免疫治疗随机对照试验中逐步实施贝叶斯与动态分析,以解读和评估频率学派结果的可靠性。

研究设计与样本

  • 选取14项未达到主要终点(总生存期)的随机对照试验(其中1项含两组两两比较),采用贝叶斯Cox模型(含动态协变量系数与时间不变模型)重新分析。
  • 纳入的试验包括7项肺癌试验及其他多种肿瘤,涉及抗PD1、抗PDL1或抗CTLA4治疗。

主要发现

  • 在非比例风险条件下,最小可检测效应(δS)在所有病例中均优于观察到的真实获益。
  • Schoenfeld检验提示6/15例存在比例风险假设违背(p<0.05)。
  • 贝叶斯Cox模型显示所有随机对照试验中获益概率>79%,治疗等效假设不太可能。
  • 总生存期曲线在中位9.1个月后出现分离;自分离后,13/15例未显示非比例性,而Wald检验在12/15个数据集中达到p<0.05。
  • 在所有病例中,带动态系数的贝叶斯Cox模型均检测到风险比的波动,2年总生存期增加是最可能的假设。

临床怎么用

  • 作者建议在所有免疫治疗随机对照试验中逐步实施贝叶斯与动态分析,以解读和评估频率学派结果的可靠性。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: The mechanism of action of immune checkpoints inhibitors hinders the writing of rational statistical analysis plans for phase III randomised clinical trials (RCTs) because of their unpredictable dynamic effects. The purpose is to illustrate the advantages of Bayesian reporting of treatment efficacy analysis in immunotherapy RCTs, in contrast to frequentist reporting. METHOD: Fourteen RCTs (one with two pairwise comparisons) that failed to achieve their primary objective (overall survival, OS) were selected. These RCTs were reanalysed using Bayesian Cox models with dynamic covariate coefficients and time-invariant models. RESULTS: The RCTs that met inclusion criteria were 7 lung cancer trials, various other tumours, with antiPD1, antiPDL1 or antiCTLA4 therapies. The minimum detectable effect (δS) was superior to the true benefit observed in all cases, in conditions of non-proportional hazards. Schoenfeld tests indicated the existence of PH assumption violations (p<0.05) in 6/15 cases. The Bayesian Cox models revealed a probability of benefit >79% in all the RCTs, with the therapeutic equivalence hypothesis unlikely. The OS curves diverged after a median of 9.1 months. Since the divergency, no non-proportionality was evinced in 13/15, while the Wald tests achieved p<0.05 in 12/15 datasets. In all cases, the Bayesian Cox models with dynamic coefficients detected fluctuations of the hazard ratio, and increased 2-year OS was the most likely hypothesis. CONCLUSION: We recommend progressively implementing Bayesian and dynamic analyses in all RCTs of immunotherapy to interpret and assess the credibility of frequentist results.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Castañon E, Sanchez-Arraez Á, Jimenez-Fonseca P, et al. Bayesian interpretation of immunotherapy trials with dynamic treatment effects. Eur J Cancer. 2021. PMID: 34933154. doi:10.1016/j.ejca.2021.11.002

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。